These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 22477068)
1. Structure and function of purified monoclonal antibody dimers induced by different stress conditions. Paul R; Graff-Meyer A; Stahlberg H; Lauer ME; Rufer AC; Beck H; Briguet A; Schnaible V; Buckel T; Boeckle S Pharm Res; 2012 Aug; 29(8):2047-59. PubMed ID: 22477068 [TBL] [Abstract][Full Text] [Related]
2. Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs. Plath F; Ringler P; Graff-Meyer A; Stahlberg H; Lauer ME; Rufer AC; Graewert MA; Svergun D; Gellermann G; Finkler C; Stracke JO; Koulov A; Schnaible V MAbs; 2016 Jul; 8(5):928-40. PubMed ID: 27031922 [TBL] [Abstract][Full Text] [Related]
3. Distinctive Low-Resolution Structural Features of Dimers of Antibody-Drug Conjugates and Parent Antibody Determined by Small-Angle X-ray Scattering. Law-Hine D; Rudiuk S; Bonestebe A; Ienco R; Huille S; Tribet C Mol Pharm; 2019 Dec; 16(12):4902-4912. PubMed ID: 31618040 [TBL] [Abstract][Full Text] [Related]
4. Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry. Rouby G; Tran NT; Leblanc Y; Taverna M; Bihoreau N MAbs; 2020; 12(1):e1781743. PubMed ID: 32633190 [TBL] [Abstract][Full Text] [Related]
5. Structural Changes and Aggregation Mechanisms of Two Different Dimers of an IgG2 Monoclonal Antibody. Zhang J; Woods C; He F; Han M; Treuheit MJ; Volkin DB Biochemistry; 2018 Sep; 57(37):5466-5479. PubMed ID: 30141909 [TBL] [Abstract][Full Text] [Related]
6. Understanding the Increased Aggregation Propensity of a Light-Exposed IgG1 Monoclonal Antibody Using Hydrogen Exchange Mass Spectrometry, Biophysical Characterization, and Structural Analysis. Bommana R; Chai Q; Schöneich C; Weiss WF; Majumdar R J Pharm Sci; 2018 Jun; 107(6):1498-1511. PubMed ID: 29408480 [TBL] [Abstract][Full Text] [Related]
7. Streamlining the polishing step development process via physicochemical characterization of monoclonal antibody aggregates. Doss HR; Raman M; Knihtila R; Chennamsetty N; Wang D; Shupe A; Mussa N J Chromatogr A; 2019 Aug; 1598():101-112. PubMed ID: 30954243 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse Model. Kijanka G; Bee JS; Schenerman MA; Korman SA; Wu Y; Slütter B; Jiskoot W J Pharm Sci; 2020 Jan; 109(1):730-738. PubMed ID: 31029572 [TBL] [Abstract][Full Text] [Related]
9. The impact of forced degradation conditions on mAb dimer formation and subsequent influence on aggregation propensity. Knight MJ; Floret L; Patel N; O'Hara J; Rodriguez E MAbs; 2022; 14(1):2127172. PubMed ID: 36198003 [TBL] [Abstract][Full Text] [Related]
10. Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Ravirajan CT; Rahman MA; Papadaki L; Griffiths MH; Kalsi J; Martin AC; Ehrenstein MR; Latchman DS; Isenberg DA Eur J Immunol; 1998 Jan; 28(1):339-50. PubMed ID: 9485213 [TBL] [Abstract][Full Text] [Related]
11. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors. Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857 [TBL] [Abstract][Full Text] [Related]
12. Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes. Bondarenko P; Nichols AC; Xiao G; Shi RL; Chan PK; Dillon TM; Garces F; Semin DJ; Ricci MS MAbs; 2021; 13(1):1887629. PubMed ID: 33615991 [TBL] [Abstract][Full Text] [Related]
13. Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions. Yageta S; Lauer TM; Trout BL; Honda S Mol Pharm; 2015 May; 12(5):1443-55. PubMed ID: 25871775 [TBL] [Abstract][Full Text] [Related]
14. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417 [TBL] [Abstract][Full Text] [Related]
15. Investigating the Degradation Behaviors of a Therapeutic Monoclonal Antibody Associated with pH and Buffer Species. Zheng S; Qiu D; Adams M; Li J; Mantri RV; Gandhi R AAPS PharmSciTech; 2017 Jan; 18(1):42-48. PubMed ID: 26340951 [TBL] [Abstract][Full Text] [Related]
16. Characterization of monoclonal antibody size variants containing extra light chains. Lu C; Liu D; Liu H; Motchnik P MAbs; 2013; 5(1):102-13. PubMed ID: 23255003 [TBL] [Abstract][Full Text] [Related]
17. Structural analysis of a therapeutic monoclonal antibody dimer by hydroxyl radical footprinting. Deperalta G; Alvarez M; Bechtel C; Dong K; McDonald R; Ling V MAbs; 2013; 5(1):86-101. PubMed ID: 23247543 [TBL] [Abstract][Full Text] [Related]
18. Investigation of anomalous charge variant profile reveals discrete pH-dependent conformations and conformation-dependent charge states within the CDR3 loop of a therapeutic mAb. Lan W; Valente JJ; Ilott A; Chennamsetty N; Liu Z; Rizzo JM; Yamniuk AP; Qiu D; Shackman HM; Bolgar MS MAbs; 2020; 12(1):1763138. PubMed ID: 32432964 [TBL] [Abstract][Full Text] [Related]